OCT 01, 2015 12:00 PM PDT
Can the World's First Animal Study Software to Emulate Clinical Trial Approaches Improve Clinical Outcome Predictability?
Presented at the Cancer Research and Oncology Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: CE
2 22 938

Speakers:
  • Vice President, Studylog Systems
    Biography
      Eric Ibsen co-founded Studylog Systems in 2003, bringing to Studylog extensive international experience in, pharmacology, animal modeling, toxicology and quality assurance in the biopharmaceutical industry. At PDL BioPharma, Ibsen conducted essential in vivo research in toxicology, oncology, inflammation and animal model development. Ibsen contributed to a successful drug discovery effort in oncology as a Scientist at Eos Biotechnology. From 1983 to 2001 he performed pharmacology research in a variety of organizations, including the Stehlin Foundation for Cancer Research, Cetus Corporation, XOMA Corporation, Bayer AG (Germany), Genentech and Theravance.

    Abstract:
    The 95% failure rate of anticancer therapeutic being approved after positive Phase III trials suggests that existing pre-clinical approaches and tools are inadequate predictors of clinical outcomes. Recent software innovations enable animal researchers to mirror multi-arm, multi-site, clinical trials with rolling enrollment and run “piggy-backed” studies under a common protocol. Attendees will learn about historical and current methods of preclinical study management and learn about the latest technological innovation, it's possibilities and impact on drug discovery.

    Show Resources
    Loading Comments...